RNS Number : 8120U IQ-AI Limited 03 August 2022   TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which

RNS Number : 9294R IQ-AI Limited 11 July 2022   IQ-AI Limited (“IQ-AI” or the “Company”)   Imaging Biometrics Announces Channel Partnership   IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce that its medical imaging analysis software, IB Clinic®, is now available via the newly launched Bayer Calantic platform. This latest distribution partnership

RNS Number : 2442N IQ-AI Limited 30 May 2022   30 May 2022   IQ-AI Limited (“IQ-AI” or the “Company”)   Result of AGM   IQ-AI Limited announces that at the annual general meeting of the Company held earlier today, all resolutions were duly passed.   The Directors of the Company accept responsibility for the

RNS Number : 3069N IQ-AI Limited 31 May 2022   31 May 2022   IQ-AI Limited (“IQ-AI” or the “Company”)   Imaging Biometrics Submits FDA 510(k) Application for IB Zero G Patented Artificial Intelligence Technology Eliminates the Need for Gadolinium-Based Contrast Agents in MRI Exams Milwaukee – 31 May 2022:  Imaging Biometrics, LLC (IB), a

RNS Number : 4440K IQ-AI Limited 05 May 2022   5 May 2022   IQ-AI Ltd (“IQ-AI” or the “Company”)   Notice of AGM   IQ-AI Limited announces that notice of the annual general meeting of the Company, to be held at Third Floor, Forum 4, Grenville Street, St Helier, Jersey, JE2 4UF on 30

RNS Number : 1476K IQ-AI Limited 03 May 2022   3 May 2022   IQ-AI Ltd (“IQ-AI” or the “Company”)   IB Neuro’s Quantitative Mapping Method Assesses Metastatic Tumors Study Shows DSC MRI Perfusion Distinguishes Tumor from Non-Tumor Tissue Milwaukee – 3 May 2022:  Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB: IQAIF)

RNS Number : 7683J IQ-AI Limited 28 April 2022   28 April 2022 IQ-AI Ltd (“IQ-AI”, the “Company” and, together with its subsidiaries, the “Group”)   Publication of Annual Report   The Board of IQ-AI Ltd are pleased to present announce that the Company’s audited financial statements for the year ended 31 December 2021.  

RNS Number : 2319E IQ-AI Limited 09 March 2022   FOR IMMEDIATE RELEASE IQ-AI LIMITED (“IQ-AI” or the “Company”) IQAI’s Sponsored Phase I Clinical Trial is Open   Milwaukee – 9 March 2022:  IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI) is pleased to announce that the sponsored Phase I clinical trial for oral gallium maltolate (GaM) is

RNS Number : 0358D IQ-AI Limited 28 February 2022   28 February 2022 IQ-AI Ltd (“IQ-AI” or the “Company”)   Total Voting Rights   In accordance with the Financial Conduct Authority’s Disclosure and Transparency Rules, IQ-AI announces that the Company has 182,621,390 ordinary shares of 1p each in issue, none of which are held in

RNS Number : 9343A IQ-AI Limited 08 February 2022   8 February 2022 IQ-AI Ltd (“IQ-AI” or the “Company”)   Issue of shares to Mayo Clinic   Further to the Company’s announcement dated 9 November 2020, IQ-AI announces the allotment of 113,781 ordinary shares of 1p each in IQ-AI (the “New Ordinary Shares”) to Mayo